OncoMatch/Clinical Trials/NCT05133882
A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML
Is NCT05133882 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Clifutinib Besylate for acute myeloid leukemia, adult.
Treatment: Clifutinib Besylate — This is a multi-center open clinical study aimed at evaluating the efficacy and safety of Clifutinib Besylate combined with chemotherapy in newly-treated adult subjects with AML
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: FLT3 ITD
the extension phase requires the subject to be positive for the FLT3-ITD mutation
Excluded: BCR ABL fusion
BCR-ABL positive leukemia
Prior therapy
Cannot have received: FLT3 inhibitor
previously received FLT3 inhibitor
Cannot have received: chemotherapy or radiotherapy for other tumors
Diagnosed as secondary to AML due to previous chemotherapy or radiotherapy of other tumors
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify